Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers
- PMID: 39900217
- DOI: 10.1016/j.canlet.2025.217512
Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers
Abstract
Colorectal cancer (CRC) represents a prototypical example of a cancer type for which inter- and intra-tumor heterogeneities remain major challenges for the clinical management of patients. Besides genotype-mediated phenotypic alterations, tumor microenvironment (TME) conditions are increasingly recognized to promote intrinsic diversity and phenotypic plasticity and sustain disease progression. In particular, acidosis is a common hallmark of solid tumors, including CRC, and it is known to induce aggressive cancer cell phenotypes. In this study, we report that long-term adaptation to acidic pH conditions is associated with common metabolic alterations, including a glycolysis-to-respiration switch and a higher reliance on the activity of phosphoglycerate dehydrogenase (PHGDH), in CRC cells initially displaying molecularly heterogeneous backgrounds. Pharmacological inhibition of PHGDH activity or mitochondrial respiration induces greater growth-inhibitory effects in acidosis-exposed CRC cells in 2D and 3D culture conditions, and in patient-derived CRC organoids. These data pave the way for drugs targeting the acidic tumor compartment as a "one-size-fits-all" therapeutic approach to delay CRC progression.
Keywords: Acidosis; Colon cancer; Metabolism; Microenvironment; Mitochondrial respiration; PHGDH.
Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S.A. reports personal fees from MSD Italia and a patent (Italian patent application No. 102022000007535) outside the submitted work. A.B. reports receipt of grants/research support from Neophore, AstraZeneca, and Boehringer Ingelheim and honoraria/consultation fees from Guardant Health. A.B. is a stock shareholder of Neophore and Kither Biotech. A.B. is an advisory board member for Neophore. L.T. reports research grants from Menarini, Merck KGaA, Merus, Pfizer, Servier, and Symphogen outside the submitted work. The other authors declare no competing interests.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous